SCHEMBL16580918

SCHEMBL16580918

COc1cccc(N(C)S(C)(=O)=O)c1Cn1ccc2cnc(Nc3ccc(N4CCN[C@H](C)C4)cc3)nc21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 5/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ FGFR2 P21802 1/20 0.47
▸ FGFR3 P22607 1/20 0.47
▸ WEE1 P30291 2/20 0.44
▸ STAT6 P42226 4/20 0.44
▸ JAK2 O60674 8/20 0.43
▸ JAK3 P52333 4/20 0.43
▸ PTK2 Q05397 1/20 0.43
▸ BRD4 O60885 7/20 0.42
▸ JAK1 P23458 3/20 0.42
▸ BRD2 P25440 3/20 0.42
▸ BRD3 Q15059 3/20 0.42
▸ BRDT Q58F21 3/20 0.42
▸ AURKA O14965 1/20 0.41
▸ CDK4 P11802 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570513 1.00 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16580919 1.00 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16580834 0.90 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16580821 0.90 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16570333 0.90 FGFR4 (0.47) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16570999 0.87 STAT6 (0.51) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16580723 0.87 STAT6 (0.51) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16569916 0.87 STAT6 (0.51) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL17958796 0.86 STAT6 (0.46) FGFR4FGFR1FGFR2FGFR3WEE1
SCHEMBL16570315 0.86 STAT6 (0.46) FGFR4FGFR1FGFR2FGFR3WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN FGFR4 385/4885FGFR1 134/4885FGFR2 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback